Seeing some nice chunks on the bid side on Level II now. I am assuming the company has already sent their results to the MHRA (supposed to be end of last month) and are expecting a recommendation by end of year.
Say it is delayed by the holidays, we should hear by early Jan. That's all that is required for this to go to $4 as Europe is not going to be swayed by politics/conflicts of interest (as in the case of FDA decision makers here).
I am expecting European approval (95% probability) since there is already a product out there with the same compounds approved by the FDA.
Give it up already. You now have two CRL's and a mismanaged company on your hands. Assume the best possible scenario in which Europe approves and you still will be waiting months for revenues and earnings to manifest themselves. The market will not run the stock up prior to approval like the good ol days. Now it is show me the goods.
Find a new stock and avoid beating this dead horse.